Consulting Agreement between Syneos Health, Inc. and Michael Bell effective December 10, 2018

Exhibit 10.1

CONSULTING AGREEMENT

This Consulting Agreement (hereinafter “Agreement”), effective as of December 10, 2018 (“Effective Date”), by and between Syneos Health, Inc. (hereinafter “Syneos Health” or the “Company”), a Delaware company, with principal offices located at 1030 Sync Street, Morrisville, North Carolina 27560, and Michael Bell (hereinafter “Bell” or “Consultant”), located at [personal address].

WITNESSETH:

WHEREAS, Syneos Health from time to time desires to contract for professional and business services to provide the Company special advice;

WHEREAS, Bell as former President, Commercial Division and Chairman of the Board of Directors of Syneos Health is particularly qualified to perform the required services due to his knowledge and experience with the Company and the industry; and

WHEREAS, Syneos Health and Bell desire to agree on terms which will govern his consulting services for Syneos Health.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and adequacy of which hereby are mutually acknowledged, the parties intending to be legally bound do hereby agree as follows:

			1

This Agreement shall commence as of the Effective Date and shall continue until the Company’s 2019 annual shareholder meeting or May 25, 2019 (the “Consulting Period”), whichever is later, unless terminated earlier as provided below. The Company may extend the Consulting Period at its discretion. The Company may terminate this Agreement at any time for Cause (as defined herein) without prior written notice. Consultant may terminate the terms of this Agreement only upon obtaining the Company’s prior written consent. “Cause” shall mean Consultant’s (i) conviction of, or plea of guilty or nolo contendere to, a felony or (ii) willful misconduct related to the Company (including, but not limited to, a willful breach of any post-employment restriction described in Section 7.4) that causes material harm to the reputation or interests of the Company.

At all times during Consultant’s engagement by the Company and thereafter, Consultant will hold in strictest confidence and will not disclose, use, lecture upon or publish any Confidential Information (as defined herein), except as such disclosure, use or publication may be required in connection with Consultant’s work for the Company or expressly authorized by the Company in writing. The obligations of confidentiality and nondisclosure hereunder shall continue after the date of termination of Consultant’s engagement. All Confidential Information provided shall remain the property of the Company and shall be returned or destroyed promptly upon request by the Company. The term “Confidential Information” shall mean, without limitation, any confidential or proprietary information or materials of the Company or its Affiliates, whether of a technical, business, or other nature, including but not limited to, information and materials which relate to operations, plans, programs, studies, techniques, processes, methodologies, products, promotional material, developments, patent applications, formulas, sponsor or client lists, information about customers, sponsors, the terms of current or pending deals, sales projections, marketing, certain financial information calculation, monthly and other periodic reports, manufacturing processes, trade secrets, basic scientific data, data systems, employment policies, formulation information, budgets, bids, proposals, study protocols, coding devices, and any other confidential data or proprietary information in connection with the Company, its Affiliates or

			2

their business affairs, including but not limited to any information relating to the operation of the Company’s and/or its Affiliates’ business which the Company may from time to time designate as confidential or proprietary or that Consultant reasonably knows should be, or has been, treated by the Company and/or its Affiliates as confidential or proprietary. Confidential Information encompasses all formats in which information is preserved, whether electronic, print or in any other form, including all originals, copies, notes or other reproductions or replicas thereof. Consultant is hereby notified that the immunity provisions in Section 1833 of title 18 of the United States Code provide that an individual cannot be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret that is made (1) in confidence to federal, state or local government officials, either directly or indirectly, or to an attorney, and is solely for the purpose of reporting or investigating a suspected violation of the law, (2) under seal in a complaint or other document filed in a lawsuit or other proceeding, or (3) to Consultant’s attorney in connection with a lawsuit for retaliation for reporting a suspected violation of law (and the trade secret may be used in the court proceedings for such lawsuit) as long as any document containing the trade secret is filed under seal and the trade secret is not disclosed except pursuant to court order. If any information that the Company deems to be a trade secret is found by a court of competent jurisdiction not to be a trade secret, such information will, nevertheless, be considered Confidential Information for purposes of this Agreement.

In no event will either party or its affiliates be liable for any indirect, special, incidental or consequential damages in connection with or related to this Agreement (including loss of profits, use, data, or other economic advantage), howsoever arising, either out of breach of this Agreement, including breach of warranty, or in tort, even if the other party has been previously advised of the possibility of such damage.

All formal or legal notices, requests, demands or other communications hereunder, other than communications reasonably deemed to be day-to-day within the duties of project management shall be in writing and shall be deemed given if personally delivered or disseminated by nationally recognized courier or certified mail within five (5) days after prior mailing to the address set forth below:

			3

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed by a duly authorized individual on behalf of each requisite party effective as of the Effective Date.

			5